256层螺旋CT血管成像术前评价肾癌肾动脉解剖及肿瘤供血动脉

目的 采用256层MSCTA观察肾癌患者肾动脉解剖及肿瘤供血动脉情况,为肾癌患者术前评估提供影像学信息。方法 回顾性分析56例经手术后病理确诊的肾癌患者(肾癌组)及300例非肾癌患者(对照组)肾动脉CTA资料,采用VR及MPR技术重建肾动脉图像,观察肿瘤供血动脉形态改变、肿瘤与肾动脉空间解剖关系及肿瘤肾外迷走供血动脉情况;比较肾癌组及对照组肾动脉解剖及变异差异。结果 肾癌组肿瘤位于左肾者31例、位于右肾者24例、双肾癌1例,肿瘤最大径(5.86±2.48)cm;肾动脉主干及分支、肾盂、肾静脉呈各种受压、受侵改变;患侧肾动脉直径分别为左侧(7.14±0.72)mm、右侧(7.04±0.70)mm,较对照组 明显增粗(P<0.05);共发现肿瘤肾外迷走供血动脉27支,分别来自脾动脉、肠系膜下动脉、膈下动脉、肾包膜动脉、肝动脉、腰动脉及肠系膜上动脉。肾癌组肾动脉变异率与对照组比较差异无统计学意义     

少见类型肾细胞癌的MRI表现及鉴别诊断

目的 观察少见类型肾细胞癌的MRI表现。方法 回顾性分析经手术及病理证实少见类型肾细胞癌10例患者的资料,患者均接受MRI平扫及增强扫描。观察分析MRI表现及其鉴别诊断价值。结果 10例中,多房囊性肾细胞癌3例,乳头状肾细胞癌4例,嫌色肾细胞癌2例,集合管癌1例;8例病灶位于右肾,2例位于左肾。4例乳头状肾细胞癌反相位信号略减低,2例嫌色肾细胞癌及1例集合管癌反相位信号未见明确减低。10例实性部分DWI序列呈高、略高信号。3例多房囊性肾细胞癌均见分隔及壁结节,其中1例分隔及壁结节明显强化,2例分隔及壁结节轻中度强化;4例乳头状肾细胞癌、2例嫌色肾细胞癌及1例集合管癌均轻度强化。结论 MRI能提供少见类型肾细胞癌更多的影像信息,对其诊断及鉴别诊断有重要的参考价值,有助于术前明确诊断。     

Prognostic significance of subclassifying stage pT3a renal tumors with fat invasion: a retrospective study of 99 patients

PurposeTo analyze the recurrence in patients with clinic stage T1 renal cell carcinoma (RCC) who were upstaged to stage T3a after partial nephrectomy (PN) using a new sub-classification criterion.MethodsA retrospective study of pathological characteristics was performed in patients who were upstaged to pT3a on the basis of fat invasion (FI).ResultsAfter analyzing the pathological findings, we proposed the following new sub-classification criteria for pT3a RCC with FI: (1) renal tumor invades the pseudo-capsule and contacts the perinephric adipose tissue directly or the tumor protrudes into the perinephric adipose tissue like a tongue (Type A); and (2) tumor nodules are distributed in perinephric adipose tissues (Type B). A significant difference was observed in the recurrence rate between the two subtypes A and B. For Type B, the recurrence rate after radical nephrectomy (RN) and PN was 15.79% and 63.64%, respectively. The recurrence rates for Types A and B after PN were 11.11% and 63.64%, respectively.ConclusionsT3a RCC with tumor nodules in perinephric adipose and/or an irregular tumor protruding into the adipose tissues lead to a higher recurrence rate. We recommend that T3a RCC be carefully analyzed and patients be treated on an individual basis.     

小肾癌超声表现与病理学改变的相关性

目的评价二维声像图及彩色多普勒成像(CDI)在小肾癌早期诊断中的应用价值。方法分析30例经病理证实的小肾癌的声像图资料,评价CDI特征与肿瘤病理学改变的相关性。结果 30例中,18例病灶以稍高回声为主,22例病灶边界清楚,22例病灶向肾表面隆起;21例病灶血流丰富,周边多呈环绕型血流信号,并向内部穿入。30例中,24例为肾透明细胞癌,2例为乳头状肾细胞癌,1例为多房囊性肾细胞癌,1例为肾嫌色细胞癌,2例肾盂浸润性尿路上皮癌,均为单侧病变;超声诊断小肾癌的准确率100%。结论超声二维声像图结合CDI对小肾癌的早期诊断及鉴别诊断具有重要临床意义。     

肾脏原发恶性孤立性纤维瘤的CT特点

目的 探讨肾脏原发恶性孤立性纤维瘤(MSFT)CT特点。方法 回顾性分析本院经手术病理证实的5例肾脏MSFT患者的临床和CT表现。结果 肿瘤位于右肾4例,左肾1例;4例来源于肾被膜,1例起自肾实质;均呈类圆形,边界清楚,见包膜,长径5.1~18.3 cm。CT平扫均呈低密度,2例见点状钙化灶,1例病灶多发且位于一侧肾脏。5例增强扫描均为皮髓期轻度强化,实质期及排泄期持续性不均匀强化,且内部见囊变坏死区。结论 当肾脏CT检查发现类圆形、边界清楚、有包膜、体积较大的肿块,瘤体内出现坏死、囊变、钙化或多发病灶,且平扫及增强扫描肿瘤密度低于周围正常肾实质密度,出现渐进性"地图"样强化时,应考虑肾脏MSFT的可能。     

肾肿瘤的三维彩色血管能量成像研究

目的　探讨三维彩色血管能量成像对肾肿瘤的诊断价值。方法　应用 3D CPA检测不同病理类型肾肿瘤 46例 ,评定血管分型 (I～III型 ) ,计算肿瘤血管指数 (VI)。结果　① 3 6例肾恶性肿瘤中 3D CPAIII型 2 6例 ,II型 10例 ;10例良性肿瘤 3D CPAI型 6例 ,II型 4例。以 3D CPAIII型诊断肾恶性肿瘤敏感性为 72 .2 % ,特异性为 10 0 %。②恶性肾肿瘤VI为 (0 .3 418± 0 .15 5 6)条 /cm3 ,良性肾肿瘤VI为 (0 .1948± 0 .0 5 73 )条 /cm3 ,二者比较差异有显著性意义 (P <0 .0 5 )。以VI >0 .2 5条 /cm3 诊断恶性肾肿瘤敏感性 77.8% ,特异性 80 %。结论　 3D CPA可清晰、完整、立体显示肾肿瘤的血管分布 ,其血管分型、血管指数有助于肾肿瘤的诊断和鉴别诊断。     

A Case of Right Renal Arteriovenous Malformation Mimicking the Symptoms of Urinary Tract Infection in the Emergency Department

BackgroundRenal arteriovenous malformation (AVM) is a rare cause of massive hematuria, and patients with renal AVM may present with symptoms like urinary tract infections in the emergency department.Case ReportA 37-year-old woman presented to the emergency department with symptoms of hematuria, urinary hesitancy, and severe suprapubic pain that had been present for a few hours. A urine examination revealed no pyuria, but urine occult blood for 3+ and a red blood cell count of >100 per high-power field. Bedside echocardiography revealed right kidney hydronephrosis and a distended bladder with a blood clot. A 3-way Foley catheter was inserted and drained 800 mL of bloody urine. A contrast-enhanced computed tomography scan was ordered that showed a 1.1-cm hypervascular tumor in the lower pole of right kidney, with active bleeding and rupture into the adjacent collecting system. Active renal tumor bleeding or renal AVM was suspected. The patient was transferred to a tertiary medical center where right renal artery angiography was arranged and disclosed an AVM with aneurysm formation at the right renal lower pole. Transarterial embolization was performed immediately to embolize the 3 feeders of the AVM.Why Should Emergency Physicians Be Aware of This?Renal AVM is a rare but potentially life-threatening cause of massive hematuria. Delayed or missed diagnosis is possible because renal AVM may present with symptoms like urinary tract infection, especially in young females. Renal artery angiography is the diagnosis of choice, and emergent transarterial embolization is now the standard of treatment.     

后腹腔镜肾部分切除术个体化方案在小肾癌治疗中的应用

目的探讨后腹腔镜下肾部分切除术(RLPN)个体化方案治疗小肾癌的可行性、安全性。方法回顾性分析2012年6月-2016年6月收治的98例实行RLPN治疗的小肾癌患者,男57例,女41例,年龄28~75岁,平均52岁,肿瘤位于左肾46例,右肾52例,直径0.8~4.5 cm,平均3.1 cm。87例(A组)小肾癌采用标准阻断肾动脉的状态下实施肾部分切除;7例(B组)外突性生长的小肾癌采用术中游离肾动脉,套橡皮条备用,试行不阻断肾动脉零缺血的状态下实施肾部分切除;4例(C组)影像学检查提示内生性小肾癌,采用腔内超声术中精确探查定位肾动脉阻断下实施肾部分切除。从术中情况、术后随访结果等分析其可行性、安全性。结果 A组87例中2例转开放手术,1例切缘阳性,改腹腔镜下肾根治性切除术,术中出血量30~350 ml,平均93 ml,手术时间70~245 min,平均127 min,术中热缺血时间20~42 min,平均26 min。B组7例外突性生长的肾癌,6例未阻断肾动脉,1例出血明显,切除肿瘤过程中,再阻断肾动脉15 min,完成肾部分切除术,出血量160~380 ml,平均220 ml,手术时间85~215 min,平均143 min。C组4例中内生性小肾癌全部手术过程顺利,出血量35~250 ml,平均85 ml,手术时间110~235 min,平均175 min,术中热缺血时间25~40 min,平均28 min。随访6~48个月,中位时间26个月,1例(肾门处3.0 cm透明细胞癌)术后18个月发现局部复发及肺部转移,予索拉非尼分子靶向治疗。结论 RLPN个体化方案治疗小肾癌安全、有效,但尚需增加例数和长期随访观察明确其远期疗效。     

肾嗜酸细胞腺瘤的临床诊治分析

目的提高肾嗜酸细胞腺瘤（renal oncocytoma,RO）的诊疗水平。方法回顾分析13例RO患者临床资料。13例患者中,男4例,女9例;肿瘤单发12例,单侧多发1例;肿瘤最大直径为1.0～6.9cm,平均3.3cm;肿瘤位于左肾上极2例,左肾中极2例,左肾下极3例,右肾上极4例,右肾中极1例,右肾下极1例。所有患者术前均行B超、IVU检查,12例行CT检查,3例行MRI检查。结果 12例术前诊断为肾癌,1例考虑为RO。13例中8例行根治性肾切除术,5例行肾部分切除术。术后病理均证实为RO。随访1～183个月无肿瘤复发或转移。结论 RO是一种临床少见的良性肿瘤,术前确诊较困难,与肾癌较难鉴别,诊断有赖于病理组织学和免疫组化检查,保留肾单位手术为首选治疗方法。     

肾集合管癌合并肾囊性透明细胞癌1例报告及文献复习

目的：探讨肾集合管癌（CDC）合并肾囊性透明细胞癌的临床病理特征及其诊断、鉴别诊断方法。方法：分析1例CDC合并肾囊性透明细胞癌患者的临床表现、组织形态学和免疫表型特征,并复习相关文献。结果：患者,男性,70岁,临床表现为无痛性血尿。影像学检查提示左肾占位。组织学示肾上极的肿瘤组织排列成不规则腺管状、乳头状,部分肿瘤细胞呈靴钉状突向腺腔内,间质纤维结缔组织明显增生,大量淋巴细胞浸润,肿瘤周围部分集合管腺上皮见异型增生。瘤细胞阳性表达波形蛋白（vimentin）、角蛋白7（CK7）、角蛋白19（CK19）、上皮膜抗原（EMA）、转录因子E3（TFE3）和E-钙黏素（E-cad）,而角蛋白20（CK20）、CD31、CD34、CD10、CD117、肾脏特异性钙黏蛋白（ksp-cad）和α-甲基酰基辅酶A消旋酶（AMACR）表达则呈阴性。肾中部囊性肿瘤组织学表现为典型的肾囊性透明细胞癌,癌细胞阳性表达CD10、波形蛋白和CK19,而CK7、CD117表达则呈阴性。结论：CDC是一种少见的高度恶性肿瘤,其诊断依赖组织病理学和免疫组化标记。由于组织起源不同,CDC合并肾透明细胞癌的概率更小,但这种合并存在的情况仍有可能。     

肾脏3.0T单体素1H-MRS定量观察

目的 分析肾脏3.0T 1H-MRS特点,探讨肾脏1H-MRS代谢物峰值的变化及其应用.方法 利用3.0T磁共振仪对50名正常志愿者及15例肾癌患者进行单体素1H-MRS成像,所用技术为定点分辨选择波谱技术.结果 15例肾癌患者共13例获得满意谱线,50名正常志愿者共48名获得满意MRS谱线.1H-MRS能够检测出肾脏中四组主要共振峰:胆固醇和不饱和脂肪酸的混合峰(Chol+Unsat)、水峰(Water)、胆碱峰(Cho)以及脂质峰(Lip)等.肾癌组Chol+Unsat/Lip峰高比约为正常组的1/5,两者之间差异有统计学意义(F=4.764,P=0.04).结论 1H-MRS能够检测出肾脏中多种代谢物,并可以定量测量、研究其谱峰变化,对肾癌的诊断可提供一定的参考价值.     

肾嫌色细胞癌的3.0TMRI表现

目的 探讨肾嫌色细胞癌的MRI表现.方法 回顾性分析14例经手术切除并病理证实的肾嫌色细胞癌的肿瘤大小、部位、形态、边界、坏死、岀血、假包膜、信号(T1WI、T2WI)、ADC值测定及强化特点.结果 所有14例均为单侧单发病例;9例(64.28%)形态规则;12例(85.71%)边界清楚;4例(28.57%)伴岀血;7例(50.00%)伴有不同程度坏死,但所有病例坏死范围均<30%;9例(64.28%)可见假包膜;T1WI 7例(50.00%)主要表现为等信号,4例主要表现为高信号,3例主要表现为低信号;T2WI 12例(85.71%)主要表现为低信号,2例主要表现为等信号.DWI 中13例病变实性区域ADC值平均为1.38×10-3 mm2 /s,正常肾脏对照ADC平均值为2.34×10-3 mm2 /s.多期动态增强扫描(11例):72.73%(8例)轻度强化,2例中等程度强化,1例明显强化.8例(72.73%)均匀强化,3例不均匀强化.5例可见病变内部轮辐状或分隔状强化.2例病灶内平扫可见粗大流空血管影走行,增强扫描可见血管强化.结论 嫌色细胞癌MR检查有一定的特异性征象,超高场强的应用尤其是多期动态增强扫描为正确诊断本病提供了可能.     

胆囊癌根治术后复发因素分析及放疗靶区指导

目的:探讨胆囊癌根治术后复发因素及复发模式,为术后辅助放疗靶区提供依据。方法:回顾性分析复旦大学附属中山医院2008—2018年收治的102例胆囊癌并接受根治术患者病例资料,明确复发因素及复发模式(包括瘤床/腹腔淋巴结复发)。其中术后辅助化疗37例,未化疗65例。结果:根治术后中位区域复发时间为12.4个月。单因素分析显示,pT、pN、黏液成分、分化与区域复发相关(P0.05)。pT、pN、分化与瘤床复发相关(P0.05);pT、pN、神经脉管侵犯与腹腔淋巴结复发相关(P0.05)。多因素分析显示,pT、pN是胆囊癌根治术后区域复发的独立预测因子(P0.05)。中位瘤床复发时间为12.5个月(95%CI 8.4～16.5个月)。中位腹腔淋巴结复发时间为10.9个月(95%CI 8.1～13.7个月)。pT/pN是瘤床复发和腹腔淋巴结复发的独立预测因子(P0.05)。术后腹腔淋巴结复发分布:8、12a、16b1高复发(40%);9、12p、13、16a2次之(20%～30%);3、5、6、7、14、16b2、17、18组较少(10%)。结论:胆囊癌根治术后复发率高,pT/pN是影响复发独立因素。即使D1淋巴结清扫,腹腔淋巴结复发仍多见。建议放疗靶区包括瘤床及部分腹腔淋巴结(8、9、12a、12p、13、16a2、16b1)。     

单孔腹腔镜根治性肾切除术治疗肾细胞癌

目的探讨应用单孔腹腔镜手术（laparo endoscopic single-site surgery,LESS）行根治性肾脏切除术治疗肾脏肿瘤的临床安全性及可行性。方法 2010年11月至2011年4月,我们应用单孔4通道（Quadport）单孔腹腔镜根治性肾脏切除术技术治疗3例肾脏肿瘤,1例为右侧中央型4.2cm肾肿瘤,另两例分别为左侧肾下极7.4cm和肾中部4.5cm肾肿瘤。经脐部切口将Quadport置入腹腔,采用5mm头部可弯腹腔镜和标准腹腔镜直器械实施标准经腹腔途径腹腔镜根治性肾脏切除术。记录患者手术时间、估计术中出血量、术中并发症、留置引流管时间、术后住院时间和术后病理等临床资料,并对结果进行分析。结果本组3例手术均由LESS完成,无加辅助通道、无转标准腹腔镜手术或开放手术完成病例。仔细实施手术步骤,避免过度钝性分离组织造成术中出血是手术顺利进行的基础。采用Quadport减少了器械间的相互干扰。根治性肾脏切除术手术操作时间分别为215、230、170min,估计术中出血量分别为100、100、150ml。本组手术无术中严重并发症。术后留置引流时间分别为4、3、2d,术后住院时间分别为8、10、8d。本组术后无继发性出血和切口感染病例。病理结果示肾透明细胞癌2例,肾嫌色细胞癌1例,无淋巴结转移,病理分期分别为pT1bN0M02例,pT2aN0M01例。本组未见肿瘤侵及肾周围组织。结论 LESS根治性肾脏切除术治疗肾脏肿瘤是安全可行的,但需要更多的研究来进一步验证。     

能谱CT术前诊断胃腺癌周围神经侵犯

目的 观察能谱CT术前诊断胃腺癌周围神经侵犯(PNI)的价值。方法 对270例拟行手术治疗的胃腺癌患者于术前1周内行能谱CT扫描,测量增强动脉期、静脉期和延迟期病灶碘浓度(IC)和标准化IC(nIC);据术后病理报告将患者分为PNI组和无PNI组,对比组间病灶IC和nIC差异,以多因素logistic回归分析筛选PNI独立危险因素,采用受试者工作特征(ROC)曲线评估IC参数诊断PNI的效能。结果 270例中,术后病理证实123例PNI(PNI组)、147例无PNI(无PNI组);组间肿瘤厚度、Borrmann分型、(术前)临床T分期(cT)、CT报告淋巴结状态、病理T分期(pT)及病理N分期(pN)差异均有统计学意义(P均<0.05)。PNI组病灶静脉期IC(ICVP)、延迟期IC(ICDP)及静脉期nIC(nICVP)、延迟期nIC(nICDP)均高于无PNI组(P均<0.001)。logistic回归分析显示,cT分期和nICDP是PNI的独立危险因素;ROC曲线示cT分期联合nICDP诊断PNI的曲线下面积(0.832)高于单一cT分期及IC参数(P均<0.0...     

Prognostic urinary miRNAs for the assessment of small renal masses

BackgroundRenal cell carcinoma (RCC) is often detected incidentally as a small renal mass (SRM; pT1a, ≤4 cm). It is clinically challenging to predict progression in patients with SRMs. This is largely due to the recent recognition of clinically progressive and non-progressive RCC-SRMs. It is critical to accurately stratify SRM patients according to risk to avoid unnecessary treatment. This is especially significant for elderly and infirm patients, where the risk of surgery outweighs mortality from SRMs.MethodsWe employed a qRT-PCR array-based approach and targeted qRT-PCR to identify and validate early, non-invasive diagnostic and prognostic biomarkers of RCC-SRMs. In total, we evaluated eighty urine samples, including 30 renal oncocytoma (≤4 cm) cases, 26 progressive and 24 non-progressive clear cell RCC-SRM (ccRCC-SRM) cases.ResultsWe identified nine urinary miRNAs which displayed significantly elevated expression in ccRCC-SRMs (pT1a; ≤4 cm) relative to renal oncocytoma (≤4 cm). Additionally, miR-328-3p displayed significantly down-regulated expression in progressive relative to non-progressive ccRCC-SRMs. Patients with elevated miR-328-3p expression had significantly longer overall survival (HR = 0.29, 95% CI = 0.08–1.03, p = 0.042) compared to patients with low miR-328-3p expression. We also found no significant association between miR-328-3p expression levels and gender, age, laterality, tumor size, or grade, suggesting that miR-328-3p is an independent prognostic biomarker.ConclusionsOur in-depth miRNA profiling approach identified novel biomarkers for early-stage ccRCC-SRMs. Pretreatment characterization of urinary miRNAs may provide insight into early RCC progression and could potentially aid clinical decision-making, improving patient management and reducing overtreatment.     

肾脏及肾肿瘤CT灌注初步研究

目的探讨肾脏及肾肿瘤的CT灌注成像方法及价值.方法对11例受检者肾脏进行同层动态扫描.扫描参数包括:层厚3 mm,在对比剂注射后第7 s开始扫描,间隔扫描时间为3 s,共扫描12层,对比剂按1 ml/kg计算给药,经肘前静脉单相注射,注射流量为3 ml/s.取得正常肾脏 (n=13)及肾肿瘤(n=9)血流量(BF)图.结果正常肾皮质BF为(157.3±20.5) ml/(min·100 ml),恶性肿瘤BF为(85.4±43.8) ml/(min·100 ml).结论 CT灌注成像可以定量评价肾脏及肾肿瘤的血流量.     

琥珀酸脱氢酶缺陷型肾细胞癌的临床病理特征

运用HE染色及免疫组织化学(immunohistochemistry,IHC)等方法分析3例琥珀酸脱氢酶缺陷型肾细胞癌(succinate dehydrogenase-deficient renal cell carcinoma,SDH-deficient RCC)的临床病理特征、免疫表型,并结合相关文献进行综合分析。在3例SDH缺陷型肾细胞癌患者中,男女均有发生,年龄22~48(平均39.33)岁,病变位于左肾1例,右肾2例。其中1例患者发生同一侧肾脏肿块2个,分别位于右肾上极和右肾下极。所有肿瘤大体边界清楚,无明确包膜,边缘呈推挤性生长,切面实性,均质,灰红或灰褐色。镜下观:肿瘤组织结构多样,呈巢状、小管状、腺泡状或实性结构,肿瘤细胞呈多边形或圆形,细胞界限不清楚,细胞质丰富,嗜酸性或透明,细胞质内可见空泡状或包涵体结构,并可见嗜酸性絮状物,细胞核圆形或卵圆形,核膜光滑规则,染色质细腻,核仁不明显,细胞核大小较一致,为低级别核;肿瘤周边可见正常肾小管或肾小球。IHC显示SDH亚单位B(SDHB)抗体表达缺失,肿块周边非肿瘤组织,包括肾小管、血管内皮细胞及炎症细胞均呈阳性表达。3例患者手术治疗后随访2~8个月,均存活。SDH缺陷型肾细胞癌具有典型的病理组织学细胞特征,确诊需要IHC标记证实。     

超声诊断囊性肾细胞癌

目的 探讨囊性肾细胞癌的声像图表现. 方法回顾性分析我院经手术及病理证实的18例肾脏恶性肿瘤的超声表现.结果 18例中超声诊断15例,误诊3例,诊断正确率83.33%.其中透明细胞癌囊性变7例,囊性肾细胞癌(透明细胞型)5例,多房性肾细胞癌3例,乳头状肾细胞癌1例,囊性壁上见透明细胞癌1例,肾母细胞瘤1例.结论 囊性肾细胞癌具有一定的声像图特点,了解其声像图特点能明显提高诊断水平.     

Kidney re-transplantation after living donor graft nephrectomy due to de novo chromophobe renal cell carcinoma: A case report

BACKGROUNDThere are few reported cases of allograft nephrectomy due to malignancy followed by successful renal re-transplantation two years later. In this paper, we report a patient who underwent kidney re-transplantation after living donor graft nephrectomy due to de novo chromophobe renal cell carcinoma (ChRCC) involving the allograft kidney.CASE SUMMARYA 34-year-old man underwent living kidney transplantation at the age of 22 years for end-stage renal disease. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil (MMF), and prednisone. Six years post-transplantation, at another hospital, ultrasonography revealed a small mass involving the upper pole of the graft. The patient declined further examination and treatment at this point. Seven years and three months post-transplantation, the patient experienced decreasing appetite, weight loss, gross hematuria, fatigue, and oliguria. Laboratory tests showed anemia (hemoglobin level was 53 g/L). Contrast-enhanced computed tomography revealed a large heterogeneous cystic-solid mass involving the upper pole of the renal allograft. Graft nephrectomy was performed and immunosuppressants were withdrawn. Histological and immunohistochemical features of the tumor were consistent with ChRCC. One year after allograft nephrectomy, low doses of tacrolimus and MMF were administered for preventing allosensitization. Two years after allograft nephrectomy, the patient underwent kidney re-transplantation. Graft function remained stable with no ChRCC recurrence in more than 2-years of follow-up.CONCLUSION De novo ChRCC in kidney graft generally has a good prognosis after graft nephrectomy and withdrawal of immunosuppression. Kidney re-transplantation could be a viable treatment. A 2-year malignancy-free period may be sufficient time before re-transplantation.